These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 28303669)

  • 1. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
    Agarwal SM; Pal D; Gupta M; Saini R
    Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.
    Liu W; Ning JF; Meng QW; Hu J; Zhao YB; Liu C; Cai L
    Drug Des Devel Ther; 2015; 9():3837-51. PubMed ID: 26229444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
    Chaube U; Bhatt H
    Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
    Ning J; Wu Q; Liu Z; Wang J; Lin X
    J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer.
    Singh PK; Silakari O
    Future Med Chem; 2017 Apr; 9(5):469-483. PubMed ID: 28362115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based pharmacophore design and virtual screening for novel potential inhibitors of epidermal growth factor receptor as an approach to breast cancer chemotherapy.
    Mahernia S; Hassanzadeh M; Sharifi N; Mehravi B; Paytam F; Adib M; Amanlou M
    Mol Divers; 2018 Feb; 22(1):173-181. PubMed ID: 29197962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosynthesis and biological evaluation of
    Huang S; Han Y; Chen M; Hu K; Qi Y; Sun P; Wang M; Wu H; Li G; Wang Q; Du Z; Zhang K; Zhao S; Zheng X
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1143-1148. PubMed ID: 29486966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
    Kancha RK; Peschel C; Duyster J
    J Thorac Oncol; 2011 Feb; 6(2):387-92. PubMed ID: 21252719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
    Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
    Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
    Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
    Sudha A; Srinivasan P; Rameshthangam P
    J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
    Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent dual ALK and EGFR T790M inhibitor.
    Jang J; Son JB; To C; Bahcall M; Kim SY; Kang SY; Mushajiang M; Lee Y; Jänne PA; Choi HG; Gray NS
    Eur J Med Chem; 2017 Aug; 136():497-510. PubMed ID: 28528303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.